Isomorphic Labs raised $5 billion in a Series C funding round led by Greenoaks and Sequoia Capital, with Andreessen Horowitz and other new and existing investors participating. The funding includes investments from Alphabet's venture divisions GV and Capital G, Thrive Capital, MGX, Temasek, and the UK Sovereign AI Fund.

The AI drug-discovery platform, spun out of Google's DeepMind in 2021, builds a drug-design engine using simulation AI models to explore chemistry and design drugs. The company said its program has yielded "positive preclinical results" in oncology and immunology. Isomorphic has partnered with pharma giants including Eli Lilly, Novartis, and Johnson & Johnson.

Isomorphic will use the new capital to continue developing its drug-design engine and expand into more types of medicine. The company plans to take drug candidates to clinical trials.

This Series C comes after a $2.1 billion Series B round in May. It follows founder and CEO Demis Hassabis stepping down as head of DeepMind to focus on drug discovery while moving into a chairman role at DeepMind. Hassabis and then-director John Jumper won the Nobel Prize in chemistry for the lab's work on AlphaFold, which predicts 3D protein structures from genetic sequences.

Bloomberg reported that Isomorphic sought funding at a $50 billion valuation, though the company did not disclose its new valuation.